Form 4: Alnylam Pharmaceuticals Director David E.I. Pyott Reports Stock and Option Transactions

Director David E.I. Pyott reports acquisition of restricted stock units and stock options in Alnylam Pharmaceuticals.

Summary

• David E.I. Pyott, a director of Alnylam Pharmaceuticals, reported transactions involving the company's stock.
• On May 8, 2025, Pyott acquired 775 shares of common stock represented by restricted stock units (RSUs) at a price of $0.0.
• These RSUs will vest in full upon the earlier of the first anniversary of the grant date or the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
• On May 8, 2025, Pyott also acquired 1,558 stock options with an exercise price of $258.35, expiring on May 8, 2035.
• These stock options will vest in full upon the earlier of the first anniversary of the grant date or the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
• Pyott also indirectly owns 27,900 shares of Alnylam common stock through the David E I Pyott Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock and option transactions by a director, indicating alignment with the company's performance but not necessarily a strong positive or negative signal.

Positives

• The acquisition of RSUs and stock options by a director signals confidence in the company's future performance.

Future Outlook

The vesting of RSUs and stock options is contingent upon continued service or retirement/resignation within a specific timeframe, aligning the director's interests with the company's performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and potential alignment with shareholder interests.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding the director's holdings and incentives.

Key Dates

Keywords

Alnylam Pharmaceuticals, Director, David E.I. Pyott, Stock Options, RSUs, Beneficial Ownership, Form 4